Investor Presentaiton

Extended durability of our I-O business Today OPDIVO (nivolumab) INJECTION FOR INTRAVENOUS USE 10 mg/mL • Opportunity Subcutaneous nivolumab Potential to benefit patients into early years of next decade Roughly 65-75% of IV US revenue potentially on-label at launch • Today Opdualag TM (nivolumab and relatlimab-rmbw) Injection for intravenous use | 480 mg/160 mg Ill Bristol Myers Squibb™ Opportunity • • Benefits patients into the next decade in 1L melanoma Potential to benefit beyond melanoma (adj. melanoma, MSS CRC, lung, and HCC) Not for Product Promotional Use 137

View entire presentation